Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer.

Cardiooncology · 2020 · PMC7643282 · PMID 33292843

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

did not reach statistical significancep = 0.150not close (p > 0.1)

While a higher proportion of patients with treatment interruption reported any anthracycline use, this difference did not reach statistical significance (64% vs. 56%, p = 0.150).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.